Siamab Therapeutics

In tech and development world, all roads do not lead to Kendall Square

Ziad2022-11-25T14:02:39-05:00 ...We moved Siamab Therapeutics from Cambridge to Newton in 2015 and, through the course of Siamab’s successful exit, subsequently launched LabShares along the Charles River in the same location. To date, we’ve hosted more than 20 companies in our incubator and are expanding. Read more >>

Angel-Funded Siamab Completes $202 Million Exit with Large Commercial-Stage Biopharma

Ziad2022-11-25T14:03:26-05:00 Siamab Therapeutics, Inc., a biopharmaceutical company developing novel glycan-targeted cancer therapeutics, has entered into a strategic agreement valued at up to $202 million with an undisclosed, large commercial-stage biopharmaceutical company under which such company will develop and commercialize antibody-based products targeting a tumor-associated carbohydrate antigen (TACA) identified by Siamab’s proprietary TACA discovery platform. Read more >>

Siamab Therapeutics Announces Publication in PLOS ONE of Positive Data from Preclinical Studies of its ST1 Antibody Therapeutic in Development for Ovarian Cancer

Ziad2022-11-25T14:04:54-05:00Siamab Therapeutics, Inc., a biopharmaceutical company developing novel glycan-targeted cancer therapeutics, today announced the publication of positive preclinical data for its ST1 antibody drug conjugate (ADC) in multiple models of ovarian cancer. Siamab’s lead ST1 program targets Sialyl-Tn (STn), a tumor-associated carbohydrate antigen (TACA), which is expressed on ovarian and other solid tumors and is associated with metastatic disease, poor prognosis, chemo-resistance, and reduced overall survival. Read more >>

Siamab Therapeutics Announces Publication of New Data on its ST1 Lead Program in the Journal Oncotarget

Ziad2022-11-25T14:05:05-05:00Siamab Therapeutics, Inc., a biopharmaceutical company developing novel glycan-targeted cancer therapeutics, today announced the publication of new preclinical data for its ST1 antibody drug conjugate (ADC) targeting the tumor-associated carbohydrate antigen (TACA) Sialyl-Tn (STn). Read more >>

Siamab Therapeutics to Present New Data on its ST1 Antibody Therapeutic Program Targeting Tumor-Associated STn and STn+ Myeloid Derived Suppressor Cells at the AACR Annual Meeting 2018

Ziad2022-11-25T14:05:05-05:00Siamab Therapeutics, Inc., a biopharmaceutical company developing novel glycan-targeted cancer therapeutics, today announced that it will present new research findings for its ST1 monoclonal antibody (mAb) therapeutic program during a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2018, being held April 14-18, 2018, at McCormick Place in Chicago. Read more >>

Siamab Therapeutics to Present New Data on its ST1 Antibody Therapeutic Program Targeting Tumor-Associated STn and MDSCs at Biotech Showcase™ 2018

Ziad2022-11-25T14:05:16-05:00Siamab Therapeutics, Inc., a biopharmaceutical company developing novel cancer therapeutics, today announced that Jeff Behrens, president and chief executive officer, will present at the 10th annual Biotech Showcase™ conference in San Francisco on Tuesday, January 9, 2018 at 1:45 p.m. PT. The conference will be held January 8-10, 2018, at the Hilton San Francisco Union Square. Read more >>

Boehringer Ingelheim highlights progress of immuno-oncology collaborations

Ziad2022-11-25T14:05:17-05:00In the last year, the firm has worked with the University of California at Los Angeles to develop a promising vaccine platform that can deliver a self-replicating RNA vaccine cargo to cancerous cells, helping the immune system to eliminate the cancer. It has also partnered with Siamab Therapeutics to identify anticancer therapeutics that target tumour-associated carbohydrate antigens, while another collaboration with AbeXXa Biologics has been formed to identify new selective molecular targets for cancer from the thousands of proteins found inside...

Siamab’s Antibody-drug Conjugates for Ovarian Cancer Seen to Succeed in Animal Models

Ziad2022-11-25T14:05:29-05:00Siamab Therapeutics’ preclinical work with anti-STn antibody-drug conjugates is moving forward, and in animal models — including primates — it showed the conjugates could safely and effectively treat ovarian cancer resistant to chemotherapy. Read more >>

Siamab Therapeutics Presents New PreClinical Safety Data

Ziad2022-11-25T14:05:29-05:00Siamab Therapeutics, Inc., a biopharmaceutical company developing novel cancer immunotherapies, today announced the presentation of new preclinical data demonstrating the safety of its novel anti-Sialyl-Tn (STn) antibody drug conjugates (ADCs) in multiple animal models, including non-human primates (NHPs). These results add to the company’s efficacy data findings showing that its anti-STn antibody therapeutics inhibit tumor progression in cell-line-derived and patient-derived xenograft (PDX) ovarian cancer and pancreatic cancer mouse models, with complete regression observed in some treatment arms. The preclinical efficacy...

Siamab Therapeutics and Boehringer Ingelheim Announce Strategic Cancer Immunology Discovery Collaboration to Develop Antibody Therapeutics Targeting Multiple Solid Tumors

Ziad2022-11-25T14:05:29-05:00Siamab Therapeutics, Inc. and Boehringer Ingelheim announced today that they have entered into a strategic discovery collaboration with the goal of developing anti-cancer therapeutics targeting tumor associated carbohydrate antigens (TACAs). Read more >>